Dr Christina Herder has more than 30 years of experience in early phase drug development and business development in the pharmaceutical industry. Christina currently holds the position as acting CEO at Idogen AB (listed on Nasdaq First Growth Market). Her previous assignments include several senior roles in among other Medivir, Swedish Orphan Biovitrum AB (Sobi) and Biovitrum. Earlier, Christina was the CEO of Modus Therapeutics, a Swedish drug development company. Christina is also a member of the Boards at PCI Biotech Holding ASA, Idogen AB, Ziccum AB and Elicera Therapeutics AB. Christina Herder holds a doctorate from the Royal Institute of Technology in Stockholm and an Executive MBA from Stockholm University.
Sign up for the Beactica newsletter to receive our latest news and updates